SCHEMBL16745368

SCHEMBL16745368

O=c1c2ccccc2c(=O)c2c1sc1c(=O)c3c(Cl)cccc3c(=O)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP1A2 P05177 2/20 0.35
CYP2A6 P11509 2/20 0.35
DYRK1A Q13627 1/20 0.35
TTR P02766 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
DAO P14920 1/20 0.33
MIF P14174 1/20 0.33
NMUR2 Q9GZQ4 1/20 0.33
MAPK1 P28482 1/20 0.33
MCL1 Q07820 1/20 0.33
S100A4 P26447 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16745358 0.97 PBRM1 (0.36) PBRM1MEN1NPC1LMNAMAPT
SCHEMBL16745355 0.95 PBRM1 (0.37) PBRM1CYP1A2CYP2A6DYRK1ATTR
SCHEMBL16745353 0.95 CYP1A2 (0.39) PBRM1CYP1A2CYP2A6DYRK1ATTR
SCHEMBL16745389 0.91 CYP1A2 (0.39) PBRM1CYP1A2CYP2A6DYRK1ATTR
SCHEMBL15551462 0.83 S100A4 (0.42) MEN1NPC1LMNAMAPTRAB9A
SCHEMBL29906291 0.83 S100A4 (0.42) MEN1NPC1LMNAMAPTRAB9A
SCHEMBL16745347 0.79 ALDH1A1 (0.41) MEN1MAPTKMT2ACYP1A2S100A4
SCHEMBL16745364 0.79 MAOA (0.49) MEN1NPC1MAPTRAB9AKMT2A
SCHEMBL16745351 0.76 MAOA (0.49) MEN1NPC1LMNAMAPTRAB9A
SCHEMBL16745401 0.76 KDM4E (0.51) MEN1KMT2ACYP1A2KDM4ECYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 US disclosed
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 US disclosed
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-28 US disclosed
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS SDHA, KLK3, BRDT PBRM1 1375/4885MEN1 50/4885NPC1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.